Merck & Co., Inc. (NYSE:MRK) Stock Holdings Lowered by Tocqueville Asset Management L.P.

Tocqueville Asset Management L.P. trimmed its stake in shares of Merck & Co., Inc. (NYSE:MRKFree Report) by 2.4% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 788,439 shares of the company’s stock after selling 19,044 shares during the period. Merck & Co., Inc. accounts for 1.5% of Tocqueville Asset Management L.P.’s portfolio, making the stock its 10th largest holding. Tocqueville Asset Management L.P.’s holdings in Merck & Co., Inc. were worth $81,170,000 as of its most recent filing with the SEC.

Several other institutional investors also recently bought and sold shares of the stock. Marquette Asset Management LLC purchased a new position in shares of Merck & Co., Inc. in the 2nd quarter worth $26,000. Your Advocates Ltd. LLP bought a new stake in Merck & Co., Inc. during the 2nd quarter valued at about $28,000. Ruedi Wealth Management Inc. lifted its holdings in Merck & Co., Inc. by 180.2% during the 3rd quarter. Ruedi Wealth Management Inc. now owns 311 shares of the company’s stock valued at $32,000 after buying an additional 200 shares in the last quarter. TFO Wealth Partners LLC raised its holdings in shares of Merck & Co., Inc. by 108.1% in the 3rd quarter. TFO Wealth Partners LLC now owns 464 shares of the company’s stock valued at $48,000 after purchasing an additional 241 shares in the last quarter. Finally, Ameliora Wealth Management Ltd. bought a new stake in shares of Merck & Co., Inc. in the 3rd quarter valued at about $50,000. 74.59% of the stock is owned by hedge funds and other institutional investors.

Merck & Co., Inc. Trading Down 0.1 %

Shares of MRK traded down $0.12 during mid-day trading on Monday, reaching $125.33. The stock had a trading volume of 1,647,433 shares, compared to its average volume of 7,936,225. The company has a debt-to-equity ratio of 0.82, a current ratio of 1.38 and a quick ratio of 1.12. Merck & Co., Inc. has a 52-week low of $99.14 and a 52-week high of $128.06. The business’s fifty day moving average is $114.58 and its 200 day moving average is $108.49. The firm has a market cap of $317.59 billion, a price-to-earnings ratio of 896.07, a P/E/G ratio of 1.62 and a beta of 0.38.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last issued its quarterly earnings data on Thursday, February 1st. The company reported $0.03 EPS for the quarter, topping the consensus estimate of ($0.09) by $0.12. Merck & Co., Inc. had a net margin of 0.61% and a return on equity of 9.07%. The firm had revenue of $14.63 billion for the quarter, compared to analyst estimates of $14.49 billion. During the same period in the prior year, the business posted $1.62 EPS. The business’s revenue for the quarter was up 5.8% compared to the same quarter last year. On average, sell-side analysts predict that Merck & Co., Inc. will post 8.6 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, April 5th. Shareholders of record on Friday, March 15th will be given a $0.77 dividend. This represents a $3.08 annualized dividend and a yield of 2.46%. The ex-dividend date of this dividend is Thursday, March 14th. Merck & Co., Inc.’s dividend payout ratio is currently 2,200.00%.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. Truist Financial lifted their price objective on shares of Merck & Co., Inc. from $122.00 to $139.00 and gave the stock a “buy” rating in a research report on Friday, February 2nd. UBS Group boosted their target price on shares of Merck & Co., Inc. from $135.00 to $148.00 and gave the company a “buy” rating in a research note on Friday, February 2nd. Morgan Stanley boosted their target price on shares of Merck & Co., Inc. from $115.00 to $118.00 and gave the company an “equal weight” rating in a research note on Friday, October 27th. Barclays boosted their target price on shares of Merck & Co., Inc. from $135.00 to $145.00 and gave the company an “overweight” rating in a research note on Friday, February 2nd. Finally, TD Cowen upgraded shares of Merck & Co., Inc. from a “market perform” rating to an “outperform” rating and upped their price objective for the stock from $125.00 to $135.00 in a research report on Thursday, January 4th. Five equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $129.68.

View Our Latest Stock Analysis on MRK

Insider Buying and Selling at Merck & Co., Inc.

In other Merck & Co., Inc. news, EVP Steven Mizell sold 50,694 shares of Merck & Co., Inc. stock in a transaction dated Friday, February 2nd. The stock was sold at an average price of $126.65, for a total value of $6,420,395.10. Following the completion of the transaction, the executive vice president now directly owns 23,619 shares of the company’s stock, valued at approximately $2,991,346.35. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 0.20% of the stock is currently owned by corporate insiders.

Merck & Co., Inc. Company Profile

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

See Also

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKFree Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.